Treatment of the seronegative spondyloarthropathies with sulfasalazine

S. H. Zwillich, S. S. Comer, E. Lee, W. A. Erdman, P. E. Lipsky

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Three patients with reactive arthritis and 2 with ankylosing spondylitis resistant to therapy with nonsteroidal antiiflammatory drugs were treated with enteric coated sulfsalazine in an open trial. Significant toxicity was not observed; 1 patient discontinued sulfasalazine because of gastrointestinal symptoms. As a group, statistically significant improvement was observed in 50 foot walk time, morning stiffness, and hemoglobin concentration. One patient went into complete clinical remission, 2 improved, 1 showed no change, and 1 worsened. Asymptomatic colonic inflammation was found in each of 4 patients examined before beginning therapy. Changes in bowel pathology did not parallel changes in joint symptoms. Sulfasalazine may be a safe and useful therapeutic modality in patients with chronic reactive arthritis or ankylosing spondylitis.

Original languageEnglish (US)
Pages (from-to)33-39
Number of pages7
JournalJournal of Rheumatology
Issue numberSUPPL. 16
StatePublished - Jan 1 1988

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Treatment of the seronegative spondyloarthropathies with sulfasalazine'. Together they form a unique fingerprint.

Cite this